Although long suspected of causing depression and other psychiatric symptoms in patients undergoing treatment for cardiovascular disease, beta-blockers are not associated with increased risk of depression, according to a systematic review and meta-analysis.
More than half of 3904 US adults with previous COVID-19 illness met criteria for moderate or greater symptoms of major depressive disorder months later, according to a study published online in a research letter in JAMA Network Open.
Nearly half of people who had recovered from acute COVID-19 reported moderate to severe depressive symptoms, researchers found in a study published in the International Journal of Environmental Research and Public Health.
The widely held assumption that individual differences underlie the variability in the association between total depression scores and antidepressant treatment may not be valid, according to a meta-analysis recently published online in JAMA Psychiatry.
Social anxiety symptoms in children exposed to maternal major depressive disorder (MDD) increased children’s risk of developing depressive symptoms over time, according to a study published in the Journal of Adolescence.
Psych Congress cochair Charles Raison, MD, will give a virtual keynote speech August 20, 2020, for the University of Louisville Depression Center’s annual benefit. The event is free and open to the public.
AXS-05, an investigational modulated-delivery tablet combining dextromethorphan and bupropion, significantly improved symptoms of depression in patients with major depressive disorder (MDD) in a recent phase 3 trial, announced developer Axsome Therapeutics Inc.